PROCEPT BioRobotics Corp
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PROCEPT BIOROBOTICS CORPORATION | ||||
| Date: | February 27, 2025 | By: | /s/ Reza Zadno | |
|---|---|---|---|---|
| Name: | Reza Zadno, Ph.D. | |||
| Title: | Chief Executive Officer | |||
SIGNATURES AND POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Reza Zadno and Kevin Waters, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Reza Zadno | President, Chief Executive Officer and Director | February 27, 2025 |
| Reza Zadno, Ph.D. | (principal executive officer) | |
| /s/ Kevin Waters | EVP, Chief Financial Officer | February 27, 2025 |
| Kevin Waters | (principal financial and accounting officer) | |
| /s/ Thomas M. Prescott | Director and Chair of the Board | February 27, 2025 |
| Thomas M. Prescott | ||
| /s/ Antal Desai | Director | February 27, 2025 |
| Antal Desai | ||
| /s/ Amy Dodrill | Director | February 27, 2025 |
| Amy Dodrill | ||
| /s/ Mary Garrett | Director | February 27, 2025 |
| Mary Garrett | ||
| /s/ Taylor Harris | Director | February 27, 2025 |
| Taylor Harris | ||
| /s/ Elisabeth Little | Director | February 27, 2025 |
| Elisabeth Little | ||
| /s/ Frederic Moll, M.D. | Director | February 27, 2025 |
| Frederic Moll, M.D. | ||
| /s/ Larry Wood | Director | February 27, 2025 |
| Larry Wood | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.